Is BRCA1 p.Asp67Ala (c.200A>C) pathogenic?

BRCA1 p.Asp67Ala (c.200A>C) is classified Conflicting classifications of pathogenicity in BRCA1 (ClinVar, Conflicting submitters, 5 submitters; last evaluated 2026-01-06). AlphaMissense: likely benign (0.1971); Very rare (popmax 0.00224%, eas); Associated with hereditary neoplastic syndrome.

What condition is associated with BRCA1 p.Asp67Ala (c.200A>C)?

BRCA1 p.Asp67Ala (c.200A>C) is associated with hereditary neoplastic syndrome, hereditary breast ovarian cancer syndrome, breast-ovarian cancer, familial, susceptibility to, 1 (ClinVar).

How common is BRCA1 p.Asp67Ala (c.200A>C) in the general population?

BRCA1 p.Asp67Ala (c.200A>C) is very rare (popmax 0.00224%, eas) (gnomAD).

What do computational predictors say about BRCA1 p.Asp67Ala (c.200A>C)?

AlphaMissense predicts likely benign (score 0.1971) — an in-silico prediction, not a clinical call.

BRCA1 p.Asp67Ala

c.200A>C · rs1060502331 · VCV867325

Conflicting classifications of pathogenicity Conflicting submitters

Classification

Conflicting classifications of pathogenicity

ClinVar

Review

Conflicting submitters ★☆☆☆

ClinVar · 5 submitters

AlphaMissense

likely benign

0.1971 · ACMG-weighted

gnomAD v4.1

Rare

very rare (popmax 0.00224%, eas)

Missense predictors

0/2 damaging

AlphaMissense, SaProt · REVEL no call

Conditions

hereditary neoplastic syndrome

Computational evidence

Protein change
AlphaMissense	0.1971	likely benign
REVEL	0.58	indeterminate
SaProt	LLR -3.05	tolerated
⇒ AlphaMissense and SaProt both call this tolerated; REVEL makes no call.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 0.45	GERP -1.4
Regional constraint	o/e 0.91	unconstrained · MANE · 78 kb · p 4.8e-05 · regional, not allelic
Overall
CADD	19.46	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.00224% East Asian · 1/44,698 alleles

Overall 0.000657% 1/152,246 alleles · very rare

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: BRCA1
Protein: p.Asp67Ala
Coding: c.200A>C
MANE Select: NM_007294
dbSNP: rs1060502331
Type: single nucleotide variant
Location: chr17:43106468 (GRCh38)
Gene constraint: LOEUF 0.885 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Structure: AlphaFold pLDDT 41.99 · 33 PDB
Residue 67: a β-strand; a UniProt-annotated variant site (in bc; benign; functionally neutral in vitro)

Full BRCA1 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

hereditary neoplastic syndrome — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary breast ovarian cancer syndrome breast-ovarian cancer, familial, susceptibility to, 1

Similar variants

BRCA1 p.Asp67= Benign ★★★ same residue
BRCA1 p.Asp67Tyr Benign ★★★ ⚠ same residue
BRCA1 p.Asp67Val Uncertain significance ★★ ⚠ same residue
BRCA1 p.Asp67Glu Uncertain significance ★ ⚠ same residue
BRCA1 p.Asp67Gly Uncertain significance ★ ⚠ same residue
BRCA1 p.Asp67Asn Uncertain significance ⚠ same residue
BRCA1 c.134+3A>T Likely pathogenic ★★★ same condition
BRCA1 c.135-1G>T Pathogenic ★★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca1-p-asp67ala (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown